Davidson Trust Co. Purchases New Position in Danaher Corporation $DHR

Davidson Trust Co. purchased a new stake in shares of Danaher Corporation (NYSE:DHR) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 6,716 shares of the conglomerate’s stock, valued at approximately $1,488,000.

Several other hedge funds have also recently added to or reduced their stakes in DHR. EP Wealth Advisors LLC acquired a new position in shares of Danaher in the 2nd quarter worth approximately $3,807,000. Puzo Michael J bought a new stake in Danaher during the second quarter worth approximately $8,624,000. Madison Asset Management LLC bought a new stake in Danaher during the second quarter worth approximately $85,451,000. First Nebraska Trust Co acquired a new position in Danaher in the second quarter worth approximately $14,106,000. Finally, Colton Groome Financial Advisors LLC acquired a new stake in shares of Danaher during the 3rd quarter valued at $592,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $220.15 on Friday. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $154.76 billion, a price-to-earnings ratio of 39.10, a P/E/G ratio of 2.71 and a beta of 0.76. The stock’s fifty day simple moving average is $211.38 and its 200-day simple moving average is $194.62.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the prior year, the business earned $0.77 EPS. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, sell-side analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is presently 28.42%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DHR. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Royal Bank Of Canada lifted their price target on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday. The Goldman Sachs Group boosted their price objective on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Finally, TD Cowen reduced their price objective on shares of Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $235.23.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.